20:37 , May 12, 2017 |  BC Week In Review  |  Company News

Clinigen launches European managed access program for Beleodaq from Onxeo

Clinigen Group plc (LSE:CLIN) launched a managed access program in Europe for Beleodaq belinostat from Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Under the program, Beleodaq will be available...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

Onxeo, University of Navarra deal

The university will conduct preclinical trials evaluating Onxeo’s Beleodaq belinostat and Livatag doxorubicin in combination with immuno-oncology compounds, including PD-1 and CTLA-4 (CD152) inhibitors in models of hepatocellular carcinoma (HCC). Results are expected next half....
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Spectrum Pharmaceuticals, Servier deal

Spectrum granted Servier’s Servier Canada Inc. affiliate exclusive, Canadian rights to develop and commercialize four cancer drugs. The deal covers Zevalin ibritumomab for follicular B cell non-Hodgkin’s lymphoma (NHL); Fotolyn pralatrexate and Beleodaq belinostat for...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Beleodaq belinostat: Phase I data

The open-label, dose-escalation, U.S. Phase I BelCHOP trial in 18 evaluable patients with PTCL showed that IV belinostat plus CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment led to an ORR of 89%,...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Belinostat: Additional Phase I/II data

Additional data from 20 patients in the Phase II portion of the open-label Phase I/II PXD101-CLN-14 trial showed that belinostat plus doxorubicin led to an ORR of 13%, including 1 complete response at cycle 2...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
03:34 , Nov 19, 2014 |  BC Extra  |  Financial News

Onxeo proposes EUR 35.4M rights offering

Orphan cancer company Onxeo S.A. (Euronext:ONXEO) proposed to raise EUR 35.4 million ($44.1 million) in a rights offering underwritten by Natixis and Oddo & Cie. The company plans to issue 7.9 million shares at EUR...
07:00 , Oct 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer; ovarian cancer Histone deacetylase (HDAC) In vitro and mouse studies suggest thioacetate-lactam carboxamide analog-based pan-HDAC inhibitors could help treat colorectal or ovarian cancer....
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) was down $0.96 to $10.54 last week after partner Gruenenthal Group submitted an MAA to EMA for Zalviso to treat moderate to severe acute pain. The submission triggered a...